An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Baylor College of Medicine
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas Newton, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT01062451
First received: February 3, 2010
Last updated: July 18, 2014
Last verified: July 2014
  Purpose

The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.


Condition Intervention Phase
Methamphetamine Dependence
Methamphetamine Abuse
Substance Abuse
Drug: Perindopril
Drug: Placebo
Drug: Candesartan
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • The dose-dependent effects of an ace inhibitor or an angiotensin receptor blocker on MA- and cue-induced craving and on the reinforcing effects of MA indexed by MA self-administration. [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    Participants demonstrating MA-induced craving will then be randomized to active study medication (perindopril or candesartan) or matched placebo (day 0). Over days 4 to 7 a variety of procedures will be completed to assess effects of MA and cue-induced craving. On day 7, reinforcing effects will be assessed will be assessed using self-administration procedures.


Secondary Outcome Measures:
  • The effects of an ace inhibitor or an angiotensin receptor blocker on subjective measures. [ Time Frame: 7 days ] [ Designated as safety issue: No ]
    On days 3 and 5, participants will receive sample doses of 15mg or 30mg MA paired with a dose of placebo saline separated by 180 min, with the order of administration randomized. Subjective effects of MA will be assessed using visual analogue scales (VAS).


Estimated Enrollment: 80
Study Start Date: May 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo treatment daily.
Other Name: Sugar pill
Active Comparator: Perindopril Drug: Perindopril
8 mg taken orally from days 0 through 7.
Other Name: Aceon
Active Comparator: Candesartan Drug: Candesartan
16 mg taken orally from days 0 through 7.
Other Name: Atacand

Detailed Description:

Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to perindopril but should lack the U-shaped dose response. Like perindopril, candesartan is used for hypertension. Whereas perindopril reduces the synthesis of angiotensin II, candesartan blocks angiotensin II receptors.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be English-speaking non-treatment-seeking volunteers.
  • Be between 18-55 years of age.
  • Meet DSM-IV TR criteria for MA dependence.
  • Have a self-reported history of using MA by the IV route.
  • Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 85-150mm Hg systolic and 45-90mm Hg diastolic.
  • Have a breathalyzer test indicating an undetectable blood alcohol level upon admission.
  • Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) < 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 x the upper limit of normal.
  • Have a baseline ECG that demonstrates normal sinus rhythm, normal conduction, and no clinically significant arrhythmias.
  • Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician and the principal investigator. Adult ADHD is allowable, as long as symptoms do not interfere with participation.
  • Demonstrate MA-induced craving, evidenced by a change in "desire" greater than 20 on a 0 to 100mm VAS.
  • Weigh between 60 and 100kg.

Exclusion Criteria:

  • Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure.
  • Have neurological or psychiatric disorders, such as: episode of major depression within the past 2 years as assessed by MINI; lifetime history of schizophrenia, other psychotic illness, or bipolar illness as assessed by MINI; current organic brain disease or dementia assessed by clinical interview; history of or any current psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months and/or current suicidal ideation/plan; history of psychosis occurring in the absence of current MA use.
  • Meet DSM-IV criteria for abuse or dependence on alcohol or other drugs, except for nicotine or marijuana.
  • Have evidence of clinically significant heart disease or hypertension, as determined by the PI.
  • Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease.
  • Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication.
  • Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, and weekly throughout the study.
  • Have any history of asthma, chronic coughing and wheezing, or other chronic respiratory illnesses.
  • Currently use alpha or beta agonists, theophylline, or other sympathomimetics.
  • Have any other illness, condition, or use of medications, which in the opinion of the P.I. and/or the admitting physician would preclude safe and/or successful completion of the study.

Rationale for Other Exclusion Criteria:

Participants with asthma or who take medications for asthma are excluded due to potential adverse interactions between treatment medications and MA. Participants who use alcohol heavily are excluded due to the potential of withdrawal symptoms in the hospital. Participants with active HIV disease are excluded to avoid potentially exacerbating their underlying illness and because of potential drug interactions. Reliable methods of birth are required to prevent pregnancy, and the use of frequent urine pregnancy tests will exclude women who become pregnant. This is important because perindopril can produce significant birth defects.

Criteria for Discontinuation Following Initiation:

Participants will be discharged if they have a positive breath test indicating use of alcohol or a urine test indicating use of illicit use of drugs while on the study, if they do not comply with study procedures, or if they do not tolerate MA.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01062451

Contacts
Contact: Thomas F Newton, MD 877-228-5777 SARP@bcm.edu
Contact: Richard De La Garza, Ph. D 877-228-5777 SARP@bcm.edu

Locations
United States, Texas
Michael E. DeBakey VA Medical Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Thomas F Newton, M.D.         
Sponsors and Collaborators
Baylor College of Medicine
Investigators
Principal Investigator: Thomas F Newton, M.D. Baylor College of Medicine
  More Information

No publications provided

Responsible Party: Thomas Newton, Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT01062451     History of Changes
Other Study ID Numbers: H-23235, R01DA023468, DPMC
Study First Received: February 3, 2010
Last Updated: July 18, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Baylor College of Medicine:
Methamphetamine
Perindopril
Candesartan
Angiotensin receptor blocker
ACE Inhibitor

Additional relevant MeSH terms:
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Candesartan
Candesartan cilexetil
Methamphetamine
Perindopril
Adrenergic Agents
Adrenergic Uptake Inhibitors
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sympathomimetics
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014